AstraZeneca CEO 'confident' Covid-19 vaccine yield will increase in Q2
Coronavirus chronicle
25 February, 2021, 10:40 pm
Last modified: 25 February, 2021, 10:43 pm
Soriot said the company aims to deliver doses from its international network, including the United States, so that it can meet volumes originally agreed in its deal with the European Union signed last year
The vaccine allegedly "stimulates broad antibody and T cell functions Photo: Medical Xpress
straZeneca's Chief Executive Pascal Soriot said on Thursday he is "confident" yields in its Covid-19 vaccine will increase in the second quarter, as the company aims to boost European Union supplies after big cuts in the first three months of the year.
Soriot said the company aims to deliver doses from its international network, including the United States, so that it can meet volumes originally agreed in its deal with the European Union signed last year.
Lower-than-expected yields - the amount of vaccine that can be made from base ingredients - at its factories hurt output in the first three months, he said.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.